Comparison of the clinical features of patients with diffuse large B-cell lymphoma with TP53 mutations in the DNA-binding domain versus patients with WT-TP53
| Clinical features . | WT-TP53 . | All TP53 mutations . | DNA-binding domain mutations . | Non–DNA-binding domain mutations . |
|---|---|---|---|---|
| No. of cases | 190 | 102 | 62 | 40 |
| 5-y survival (P) | 45 | 24 (.014) | 19 (.008) | 32 (.412) |
| Median survival, y (P) | 4.5 | 1.3 (< .001) | 1.0 (< .001) | 1.8 (.158) |
| Complete remission, % (P) | 69 | 57 (.089) | 54 (.076) | 62 (.527) |
| Disease progression, % (P) | 12 | 17 (.325) | 21 (.143) | 10 (.999) |
| Clinical features . | WT-TP53 . | All TP53 mutations . | DNA-binding domain mutations . | Non–DNA-binding domain mutations . |
|---|---|---|---|---|
| No. of cases | 190 | 102 | 62 | 40 |
| 5-y survival (P) | 45 | 24 (.014) | 19 (.008) | 32 (.412) |
| Median survival, y (P) | 4.5 | 1.3 (< .001) | 1.0 (< .001) | 1.8 (.158) |
| Complete remission, % (P) | 69 | 57 (.089) | 54 (.076) | 62 (.527) |
| Disease progression, % (P) | 12 | 17 (.325) | 21 (.143) | 10 (.999) |
WT indicates wild-type.